Abbott Labs News
Most Popular Abbott Labs Story
Abbott buys Facet Biotech for $450M
Abbott has succeeded where Biogen Idec once failed. The company announced late Tuesday that it's purchasing Facet Biotech for $450 million, or $27 a share. That's 67 percent premium over the... Read more...
Latest Headlines
- March 9, 2010
- February 4, 2010
- February 2, 2010
- November 12, 2009
- September 28, 2009
- September 24, 2009
- July 15, 2009
- January 20, 2009
- December 17, 2008
- December 16, 2008
- September 28, 2008
- August 22, 2008
- June 13, 2008
- March 20, 2008
- March 19, 2008
- February 22, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
